Meeting Patient Needs Through Flexible Pharmaceutical Manufacturing
Pharmaceutical manufacturing at scale requires flexibility, cGMP compliance and advanced technology to ensure safe, reliable medications for patients.
READ MORE
IN THE NEWS
Pharmaceuticals
Blow-Fill-Seal: How Ritedose Is Setting the Standard in Pharmaceutical Manufacturing
Blow-Fill-Seal manufacturing is transforming sterile pharmaceutical production, and Ritedose is setting the standard through innovation, quality systems and scalable CDMO expertise.
READ MORE
Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US
This overview explores Ritedose, the largest U.S. pharmaceutical CDMO, and how its aseptic Blow-Fill-Seal technology supports large-scale branded and generic drug manufacturing.
READ MORE
How Ritedose Supports a Stable and Reliable Medication Supply
Learn how Ritedose safeguards patients’ access to critical medications with responsive, high-quality pharmaceutical manufacturing.
READ MORE
Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position
Ritedose is investing $17M to expand its cGMP labs, adding a 10,000 sq. ft. analytical chemistry facility and a 6,000 sq. ft. microbiology expansion to boost drug development and CDMO capabilities.
READ MORE
How Blow-Fill-Seal Technology Ensures Sterile Medication Delivery
Discover how Ritedose leads the industry in delivering safe, scalable, and contamination-free drug products through advanced BFS innovation.
READ MORE
Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*—Addressing Nationwide Shortage of the Essential Drug
COLUMBIA, SC May 20, 2025 —Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract development manufacturing organization (CDMO) in the US specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology, received US Food and Drug…
READ MORE
Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness
COLUMBIA, SC May 1, 2025 — Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), was granted approval by the US Food and Drug Administration (FDA) to manufacture and market generic formoterol fumarate inhalation solution (20 mcg/2 mL), a treatment…
READ MORE
Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre
COLUMBIA, S.C. April 16, 2025 – Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company’s capacity.
READ MORE
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
September 17, 2024 — The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona…
READ MORE
FEATURED NEWS
RECEIVE THE LATEST NEWS
Get a healthy dose of all things Ritedose. Subscribe now for breaking news alerts, updates, previews, and more.